News & Updates
Filter by Specialty:
Add-on digital therapeutics more cost-effective than standard treatment for essential hypertension
The combination of digital therapeutics (DTx) with the treatment-as-usual (TAU) strategy for essential hypertension is more cost-effective than TAU alone, a recent Japan study has found.
Add-on digital therapeutics more cost-effective than standard treatment for essential hypertension
13 Oct 2022
Early noninferior to delayed NOAC initiation after stroke in AF patients
Early initiation of nonvitamin K antagonist oral anticoagulants (NOACs) after acute ischaemic stroke in patients with atrial fibrillation (AF) appears to yield similar outcomes when compared with delayed initiation, as shown in the results of the TIMING* study.
Early noninferior to delayed NOAC initiation after stroke in AF patients
13 Oct 2022
Telmisartan does not deliver in peripheral arterial disease
Treatment with the angiotensin receptor blocker telmisartan does not appear to confer improvements on walking performance in patients with lower extremity peripheral artery disease (PAD), according to the TELEX trial.
Telmisartan does not deliver in peripheral arterial disease
11 Oct 2022
Liver stiffness, but not fatty liver disease, linked to atrial fibrillation
Fatty liver disease does not seem to contribute to prevalent or incident atrial fibrillation (AF), but higher liver stiffness does, particularly among individuals without steatosis, reports a recent study.
Liver stiffness, but not fatty liver disease, linked to atrial fibrillation
11 Oct 2022
Does age at diagnosis affect diabetes outcomes?
Individuals who are diagnosed with type 2 diabetes (T2D) at age ≤40 years have a greater risk of cardiovascular disease (CVD) and mortality than same-aged individuals without T2D or individuals diagnosed with T2D in later life, according to a study from Korea presented at EASD 2022.